Introduction
The scale to which the absorbed dose can be determined from clinical nuclear medicine images is most often limited by the spatial resolution of the imaging system used. Due to low spatial resolution tissues may appear to have a homogenous activity distribution while the actual pattern of energy deposition remains quite heterogeneous. One methodology that can be applied to investigate absorbed dose distribution at a finer scale is to combine small-scale dosimetry models and patient pharmacokinetic data. A tissue where this is important and relevant is the testis. It is well known that the testis is a highly radiosensitive organ and considered a critical tissue in both diagnosis and therapy with ionizing radiation. The limit for deterministic effects, that is, temporary sterility, is only 150 mGy, while permanent sterility may occur at absorbed doses of 2 Gy y −1 or single exposures of 3.5-6 Gy (ICRP 1984) . However, less is known about the occurrence of radiation-induced cancer in the testes (Yousif et al 2010) , but any radiation-induced mutation in the germ cells that may cause genetic disease in humans has not been reported (BEIR 2006) . However, in radiation protection and risk estimates, this cannot be disregarded and the ICRP has assigned a tissue weighting factor of 0.08 for the gonads (ICRP 2007) .
One example in radioimmunotherapy where there is a potential risk of toxic effects on the gonads is the treatment for non-Hodgkin's lymphoma with 90 Y-Zevalin ® (Spectrum Pharmaceuticals, Inc. USA).
For instance, after a treatment male patients may experience temporary or permanent sterility, and according to EANM's guidelines, treatment of males of fertile age should be carried out with caution (Tennvall et al 2007) . 90 Y-Zevalin ® therapy is administered by an intravenous infusion (normally 15
MBq kg −1 with a maximum of 1.2 GBq), and absorbed dose values to the testis have been reported to fall between 2.2 and 9.1 mGy MBq −1 (Chiesa et al 2009; Cremonesi et al 2007; Fisher et al 2009; Shen et al 2005; Sjögreen-Gleisner et al 2011; Wiseman et al 2003a; Wiseman et al 2003b) . Estimated mean absorbed doses to the testis from 111 In-Zevalin ® , have been reported to fall between 0.2 and 2.4 mGy MBq −1 Wiseman et al 2003b) . Because the radionuclide 90 Y is a pure  −emitter, imaging is considered difficult in clinical settings. Instead, imaging the biodistribution of 90 Y-Zevalin has generally been performed using 111 In-Zevalin as a surrogate, by the assumption that the biological behavior of the two Zevalin-agents is identical (Sjögreen-Gleisner et al 2011) . Likewise, the majority of reported dosimetry studies are based on 111 In-Zevalin imaging. In some cases, an 111 In-Zevalin study has been used for planning the absorbed dose of a subsequent 90 Y-Zevalin treatment (Sjögreen-Gleisner et al 2011) .
The absorbed doses reported above refer to the average absorbed dose to the whole testis, which according to conventional MIRD dosimetry assumes a homogenous activity distribution within the organ . However, the absorbed dose to the regions with radiosensitive germ cells may be significantly higher, or lower, depending on the true activity distribution, which is likely to be non-homogenous among different testicular compartments. For instance, it has previously been shown in multilevel autoradiography studies that 111 In-transferrin is highly non-homogeneously localized in the testis. The uptake was reported to be mainly localized in the interstitial tissue, but with an uptake in the spermatogonial region well above the average level (Jönsson et al 1992b; Jönsson et al 1992c) .
It is well known that germ cells have different radiation sensitivities, with the highest for undifferentiated spermatogonia near the basal cell layer. The more mature sperm cells migrating toward the lumen have the lowest sensitivity (Centola et al 1994; Meistrich 1986 ). Hoyes et al. (1994) demonstrated that activity localization in the intratesticular tissue may result in spermatogenic damage (Hoyes et al 1994) and that human spermatozoa in vitro appears to accumulate transferrin-binding metals such as 111 In (Hoyes et al 1998) . Some radiometal-based radiopharmaceuticals have also been reported to be retained in the testicular tissue (Jackson et al 1991; Jönsson et al 1992a; Nettleton et al 2004; Rao et al 1983) . However, their precise localization is unknown and remains to be determined.
Another source region that may contribute significantly to the absorbed dose to the sensitive germ cells is circulating plasma-bound activity, which is localized in the vasculature of the interstitial tissue.
A need has been established for developing more detailed dosimetry models based on tissue structures in internal dosimetry (Howell et al 2006; ICRU 2002; Sgouros et al 2009) . Our group recently published a small-scale dosimetry model developed for detailed testis dosimetry (Larsson et al 2012) .
This model permits the calculation of the absorbed dose to different target cells in the testicular tissue from radionuclides used in nuclear medicine, with a choice of source regions (i.e., the interstitial tissue and the different cell layers in the seminiferous tubules). The latter corresponds to the sites of spermatogenesis, the complex process where germ cells proliferate and transform into spermatozoa.
The aim of the present study was to calculate the absorbed dose to the spermatogonia region for 111 In Zevalin ® , based on the new small-scale dosimetry model and the S-values calculated therein, assuming a hypothetical but realistic activity micro-distribution. The biokinetics were obtained from blood sampling and whole-body imaging of four patients, along with subsequent image-based quantification of whole-testes activity. To refine and resolve the small-scale distribution activity, a compartmental model was used for separating the activity into vascular and extravascular compartments; this was solved by combining image-based activity estimates with blood sampling (Nickel et al 2009; Sjögreen-Gleisner et al 2007) .
Material and Methods

Patient data
Data from four patients were included, referred for pre-therapy imaging with 111 In-Zevalin ® (Spectrum Pharmaceuticals, NV, USA) for absorbed dose planning prior to RIT of B-cell lymphoma with 90 Y-Zevalin ® (Spectrum Pharmaceuticals, NV, USA). The patients were intravenously injected with 290-300 MBq 111 In-Zevalin ® (table 3) . Whole-body planar imaging was performed at seven points: 1, 24, 48, 72, 144, 166, and 192 h after injection. A dual-head Discovery SPECT/CT VH system (General Electric, Milwaukee, WI) was used for image acquisition. Anterior and posterior whole-body images were acquired using a 15% energy window centered over the 245-keV photopeak, employing mediumenergy general-purpose collimators. For the purpose of attenuation correction, a whole-body planar transmission image (X-ray scout image) was acquired at 24 h. For quantification of the 111 In-Zevalin ® distribution, images were exported in the DICOM image format to an independent computer platform for further processing in the LundADose software (Sjögreen et al 2005) . In brief, the activity quantification included several steps: a) explicit correction for scatter in the anterior-posterior whole-body images by deconvolution (Sjögreen-Gleisner 2012) ; b) calculation of a geometric mean image by pixel-by-pixel multiplication of scatter-corrected anterior and mirrored posterior projections; and c) pixel-based attenuation correction using a co-registered whole-body attenuation map calculated from the X-ray scout image (Sjögreen-Gleisner and Ljungberg 2012) . The image obtained from these steps was a count-rate projection without effects of attenuation or scatter, i.e. as if the activity were situated in air, and could thus be converted to an activity projection using a measured value of the system sensitivity in air (cps MBq −1 ) for 111 In. Note that this procedure did not use the amount of injected activity for calibration, and thus represented an independent quantification of the activity distribution in the patient. By careful manual delineation of regions of interest (ROI) over the testes region in the images at each point in time, the regional activity was quantified using the image processing program ImageJ (Research Services Branch, National Institute of Mental Health, Bethesda, Maryland, USA).
Blood samples were collected at 5 and 45 min and at 3, 6, 24, 48, 72, 144, 168 and 190 h after administration. Plasma was centrifuged for separation, weighed, and the activity was measured in a calibrated well-type NaI(Tl) detector (1282 CompuGamma CS; Wallac).
Compartmental modeling
Total activity in the testis was divided into a vascular and an extravascular part by compartmental analysis (Nickel et al 2009; Sjögreen-Gleisner et al 2007) . The model used is shown in figure 1 . The total activity in the testes at time t, ( ), was described as
where ( ) and ( ) are the activities (MBq) within the vascular and extravascular spaces of the testes. The curve ( ) was determined as part of model optimization by minimizing its deviation from the measured testes activity values. The curve ( ) was described as the vascular activity in total body, ( ), multiplied by a regional vascular fraction, , denoting the fraction of the total-body vascular volume contained in testes:
The curve ( ) was described as
where ( )and ( ) (MBq/g) denote activity concentrations, and are total-body volumes (mL), and and (g/mL) denote mass densities, of plasma and whole blood, respectively. Values of and were set to 1.03 g/mL and 1.06 g/mL, respectively (ICRP 2002) . For optimization of the curve ( ) measured values of activity concentrations in plasma and whole blood were used.
Moreover, the injected activity, , was modeled as a bolus at time zero with a value equating the administered amount for the patient, which in equation 3 introduced the constraint that (0) should equal . The disappearance of activity from blood was due to extravasation and uptake in different tissues and organs. To simplify the analysis, the model for extravascular activity was limited to the testes and a remainder compartment. The activity in total body, ( ), was thus modeled as the sum
The curve ( ) was determined as part of model optimization by minimizing its deviation from measured values of total-body activity from image-based quantification. Moreover, at the time of administration the values of (0) and (0) were equal to zero, thus implying that
should equal (0), which introduced further constraints for the free parameters and in equation 3. The activities in the extravascular compartments were determined by solving the linear differential equations
where the k parameters are rate constants with v, tes, rem, exc denoting compartments vascular, testes, remainder, and excretion, respectively, and is the rate of physical decay (h -1 ). This model was implemented in SAAM II (The Epsilon Group, VA, USA), which is a commercial software package that supports compartmental modelling through a graphical user interface. The model was solved using a Cash-Karp variant of the embedded Runge-Kutta method (Press et al 1992) and assuming data variance described by Poisson statistics. The cumulated activities of the testes compartments, i.e. total, vascular, extravascular, and the associated uncertainties, were calculated by numerical integration. An integration time of 1000 h was chosen so that no further increase in the cumulated activities occurred.
The fraction of cumulated activity in the respective compartments was then determined, with its uncertainty estimated by error propagation.
Calculation of the absorbed dose
The absorbed dose to the spermatogonia (the most radiosensitive cells in the testis) was calculated It has been reported in the literature that the diameter of the seminiferous tubule varies between 150 and 300 m (Holstein et al 2003; ICRP 2002) . In order to investigate the uncertainty originating from the unpredictable geometry of the testis, the previously fixed size of the seminiferous tubule radii was varied between 100 and 200 m. Since the diameter of the male germ cells of different stages as well as the extension of their cell layers are considered to be relatively equal, the layer thickness seen from the basement membrane was kept fixed, only allowing change in the lumen thickness. Monte Carlo simulations (MCNP5 1.51, Los Alamos, NM: Los Alamos National Laboratory) of energy deposition were then carried out with this modified geometry to calculate new S-values. The number of particles simulated was set to get a statistical uncertainty below 1%. Although the original model allows one to choose several optional source-target regions within the testis tissue, only three source regions were selected in the present study, in order to characterize a hypothetical but realistic uptake of radioactivity in the i) interstitial tissue, ii) spermatogonia, and iii) lumen (see figure 2 ). The uptake in the interstitial tissue may then represent the most probable case whereas an uptake by spermatogonia represent a worst case situation.. 
where D r T is the absorbed dose to a target region , and is the cumulated activity in source region . The is the mean energy emitted per nuclear transformation from the source and is the fraction of the radiation energy emitted from the source region, , that is absorbed in the target region, . The product of the quantities and divided by , the mass of the target region, is designated by the S-value, which is radionuclide-and anatomy-specific. 
Results
Biokinetics and Compartment Analysis
The results for the compartment analysis of the biokinetic data of testes from the individual patients are given in figure 3 A representative result of activity in total body and in vascular spaces for patient 2 is shown in figure   4 . In similar to results in Figure 3 , comparison of model-derived curves of the activity in plasma and whole blood in total body was achieved by scaling the measured values of the activity concentrations by the factors ( • ) and ( • ), for plasma and whole blood, respectively. As seen, curves obtained from compartment modeling fit measured data very well, and equally good fits were obtained for the other patients. The total-body blood volumes were obtained to 4830±76 mL, 5144±41 mL, 5738±65 mL, and 4833±65 mL (±1 standard deviation), for patients 1-4, respectively, and plasma volumes obtained were 3292±41 mL, 3452±33 mL, 3632±49 mL, and 3010±46 mL, for patients 1-4, respectively. The standard deviations obtained were thus between 0.81% and 1.58% of the determined values. Values obtained compare well with population reference values of 5300 mL and 3000 mL, for whole blood and plasma volumes, respectively (ICRP 2002) . 
Absorbed dose calculation
The absorbed dose to the testis was calculated individually for the four patients according to their biokinetic data (table 3) for the three cases of activity distribution. These are given in table 4A-C. In case 1, the absorbed dose to the target regions is calculated assuming that 100% of the testis activity is localized homogenously in both the vascular and the extravascular space in the interstitial tissue (IT).
In this case no activity has penetrated the blood-testes barrier, and all exposure of the cells in the seminiferous tubules originates from radiation emitted in the interstitial tissue. In case 2, based on the compartment analysis, around half of the decays are in the vascular space and half in the peripheral region of the tubule, i.e. the site of the radiosensitive spermatogonia, see table 4 for individual values.
Finally, case 3 exemplifies when the activity in the tubule is localized more centrally, i.e. in the lumen containing radio-resistant sperm. The absorbed doses in each region are compared to the mean absorbed dose to the whole testis.
As expected, the source region receives the highest absorbed dose due to the self-dose from low energy conversion and Auger electrons (see table 2 ). It is interesting to note that when the IT accounts for all activity, the adjacent spermatogonial region may receive an absorbed dose that is 11% lower than the mean absorbed dose to the whole testis, i.e. 0.44 and 0.49 mGy MBq −1 , respectively (case 1; 
Uncertainty due to geometry variations
In the cases above, a fixed diameter of 250 m was used for the seminiferous tubule, according to our published model (Larsson et al 2012) , To relate influence of the geometry on the absorbed dose profile to our three cases, the radius of the seminiferous tubule was varied between 100 and 200 m. The results of the simulation of modified S-values with this slightly altered geometry are presented in figure 5 , which shows the ratio between the absorbed dose to respective target regions and the mean absorbed dose to the whole testis for the three cases. Hence, the source is either the interstitial tissue (e.g. blood vessels, macrophages, and Leydig cells), the spermatogonium (spermatogonia) or the lumen (mature spermatids), and the absorbed dose ratio profiles are shown throughout the seminiferous tubule starting from the basement membrane (lamina propria). The calculations show the spermatogonia 111 In self-dose to whole-testis absorbed dose ratio increasing from 1.61 to 2.27 (26%) as the seminiferous tubule radius is enlarged from 100 to 200 m. This is mainly due to the changes in weight, but a 15% reduction in the absorbed fraction is observed as well.
The cross-dose from other regions to the spermatogonia also changes as the radii of the seminiferous tubules are varied, due to the increased distance between them. The absorbed dose ratio from IT to spermatogonia is increased from 0.89 to 0.95, whereas the absorbed dose ratio from lumen to spermatogonia is decreased from 0.83 to 0.79. Using the biokinetic data from the patients, the absorbed dose in mGy per MBq administered activity is presented concurrently and can be read on the right axis in figure 5 .
Discussion
The testis is considered a critical tissue in both diagnosis and therapy with ionizing radiation, with very low absorbed dose limits for both temporary and permanent sterility. For external exposure, it is relatively simple to measure and determine the absorbed dose to a critical organ, and different precautions have been developed to protect organs at risk. However, the precautions for diagnostic Xray examinations (e.g., scrotum-capsule shields) and external radiotherapy (e.g., field techniques and shaping) are in principle impossible to use in nuclear medicine procedures. On the other hand, the accuracy of internal dosimetry has been considerably improved since the introduction of the MIRD methodology (Loevinger and Berman 1976) for making dose estimations to predict possible organs at risk. Discussions on dosimetry often concern uncertainty in the determination of the absorbed dose and the relevance to possible stochastic or deterministic damages. In nuclear medicine, the main concern has so far been stochastic (long-term) effects, but the increasing use of very high activities in radionuclide therapy now also include concerns over deterministic effects to critical organs, such as bone marrow, intestines, kidneys and gonads. One main obstacle in conventional dosimetry is the lack of knowledge of detailed activity localization within the tissue, and the activity is therefore simply assumed to be homogenously distributed throughout the organ. This assumption is mostly based on activity biokinetic data obtained from SPECT/PET imaging with insufficient spatial resolution for accurate dosimetry. In this work planar imaging and was used for quantification of the activity in testes. We recognize that, generally, SPECT imaging is regarded a superior technique for activity quantification mainly due to superimposing activity in overlapping structures seen in planar images.
However, this problem was not so apparent for the testes, being a body region, which is less overlapped by other structures. Moreover, the testes are rarely covered by the SPECT field-of-view, as was the case for the patients included in this study. Owing to the small extension of the testes compared to other body regions it was considered important to make explicit attenuation correction, and was achieved using a pixel-based quantification scheme where an X-ray scout image is used as attenuation correction map. The internal dosimetry community continuously discusses the necessity for improvements to bring about more detailed tissue and cellular dosimetry (Hobbs et al 2012; Howell et al 2006; ICRU 2002; Sgouros and Hobbs 2014; Sgouros et al 2009) . One direction has been the development of detailed small-scale dosimetry models but the practical use is so far unfortunately limited due to the difficulties in determining detailed activity localization for the tissue in question.
However, small-scale dosimetry models can serve as an essential bridge between macroscopic and cellular dosimetry. For instance, such models may act as an indicator of uncertainties arising from intrinsic geometry variation at tissue level, and are especially relevant to investigating the influence of the energy absorption pattern of low-energy electrons and soft X-rays. The three cases studied in this work are hypothetical but have support in the literature-for instance, the most probable site of radiopharmaceutical localization is the interstitial tissue. This is because the blood-testis barrier consists of the Sertoli cells, which efficiently inhibit harmful agents from entering the seminiferous epithelium (Bart et al 2002) . However, 111 In and some other radiometals have been reported to traverse the blood-testis barrier, probably by utilizing the iron-transferrin pathway, to accumulate inside the seminiferous epithelium (Hoyes et al 1996; Hoyes et al 1998; Hoyes et al 1994; Jönsson et al 1992b; Nettleton et al 2004) .
Based on biological pre-therapy patient data, the macroscopic dosimetry resulted in absorbed doses to the whole testis of 0.5 mGy MBq −1 from 111 In-Zevalin © , which is the same level as reported previously (Shen et al 2005; Wiseman et al 2003a) . However, although the detailed localization of 111 In-Zevalin © in the patient testis is not yet known and remains to be explored, it is obvious from the present smallscale dosimetry model that the absorbed dose is highly dependent of the site of activity localization and on natural geometric variations of the interstitial tubules. As a worst case, i.e. the basal compartment as the source, the absorbed dose to spermatogonia might exceed the whole testis mean absorbed dose by a factor of 1.6-2.3, depending on the radius of the seminiferous tubule. On the other hand, if no activity at all passes the blood-testis barrier, i.e. all activity is localized in the interstitial tissue, the absorbed dose to the spermagonia is about 10 % below the mean absorbed dose to the whole testis. Still, precautions have to be taken since even a diagnostic activity may reach the limit for deterministic temporary effects and enhanced risk for stochastic effects.
It can be seen that the average absorbed dose to the whole testis is 0.49 mGy MBq −1 or approximately 150 mGy if 300 MBq 111 In-Zevalin © is administered, consequently hitting the limit of absorbed dose and causing temporary sterility. Unlike for 111 In, a heterogeneous localization of 90 Y in the testis is not critical for the absorbed dose due to its long-range beta particles, and the absorbed dose will then be nearly the same throughout the testis, no matter the activity localization in different testicular compartments. The minor differences in S-values can be seen in table 1b. Thus, with the same biokinetics as 111 In-Zevalin © , the absorbed dose from the 90 Y-Zevalin © should yield an average absorbed dose of 3.30 mGy MBq −1 . A treatment with the recommended therapy activity (i.e. 11.1 MBq kg −1 or a maximum of 1200 MBq) should then result in a testis absorbed dose of about 4 Gy (Larsson et al 2012) and undoubtedly result in permanent sterility. As a consequence, caution is recommended for the treatment of young male patients and semen cryopreservation may be appropriate prior to treatment (Tennvall et al 2007) .
Conclusion
Small-scale dosimetry models combined with clinical patient biokinetics and compartment modeling may potentially serve as a bridge between organ and tissue dosimetry, and the interpretation of intrinsic geometric variation and its uncertainties in absorbed dose. In this paper, we focused on the dosimetry for the testicle and presented significant differences in the absorbed dose to the radiosensitive germ cells depending on the location of the radioactive source region and geometry variations of the seminiferous tubule.
